--- title: "Ceragon Networks Ltd. Stock 12‑Month Price Target Raised to $4.67, Implies 86% Upside" type: "News" locale: "en" url: "https://longbridge.com/en/news/286956894.md" description: "Ceragon Networks Ltd.'s stock price target has been raised from $4.54 to $4.67, suggesting an 86% upside based on the May 18 closing price. The consensus rating remains a 'Buy' from 6 analysts, with all recommending 'Buy' and none suggesting 'Hold' or 'Sell'." datetime: "2026-05-19T19:20:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286956894.md) - [en](https://longbridge.com/en/news/286956894.md) - [zh-HK](https://longbridge.com/zh-HK/news/286956894.md) --- # Ceragon Networks Ltd. Stock 12‑Month Price Target Raised to $4.67, Implies 86% Upside - According to estimates from 6 analysts, Ceragon Networks Ltd. stock's average price target has risen from $4.54 to $4.67, with forecasts ranging from $3 to $9 per share - Based on the May 18 closing price, the updated target implies approximately 86% potential upside - Consensus rating remains at “Buy” across 6 covering analysts, with 6 Buys, 0 Holds and 0 Sells Explore more price target data and ratings for Ceragon Networks Ltd. on the , and track all previous and future analyst recommendations for Ceragon Networks Ltd. in the dedicated News Flow. **Disclaimer** Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice. ### Related Stocks - [CRNT.US](https://longbridge.com/en/quote/CRNT.US.md) - [FDS.US](https://longbridge.com/en/quote/FDS.US.md) ## Related News & Research - [Ceragon Networks Ltd. (NASDAQ:CRNT) Given Average Rating of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/287094968.md) - [Ceragon Q1 revenue beats estimates on India demand](https://longbridge.com/en/news/286900985.md) - [Best Buy leak hints GTA VI pre-orders may start May 18](https://longbridge.com/en/news/286472709.md) - [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md) - [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)